Supplementary Figure S8 from Integrated Omics and Multicohort Analyses Identify an Enhancer Variant Linking Ferroptosis to Precision Therapy in Prostate Cancer

This is a Cohort Study study (also classified as: Experimental Study).

Key Points

NCOA4 alters sensitivity to ferroptosis-inducing drugs in prostate cancer cells, enhancing treatment efficacy.
Key evidence indicated by in vitro assessments reveals that NCOA4 plays a significant role in drug response.
Analysis incorporated multicohort data to explore the relationship between enhancer variants and cancer therapy outcomes.
These findings highlight the potential for precision therapy strategies, emphasizing the importance of genetic factors.

We only have this paper's title and publication details.

Observational analysis shows NCOA4 impacts drug sensitivity in prostate cancer, suggesting new therapeutic approaches.

NCOA4 affects prostate cancer sensitivity to ferroptosis-inducing drug in vitro

No takes yet. Share an insight, caveat, or question.

Ma et al. (2025) studied this question.

View Full Paper

Ask AI

Bookmark

Share